Ultragenyx Pharmaceutical Inc. (RARE)
收市後：
| 前收市價 | 43.69 |
| 開市 | 43.74 |
| 買盤 | 45.04 x 200 |
| 賣出價 | 45.12 x 200 |
| 今日波幅 | 43.13 - 45.58 |
| 52 週波幅 | 31.52 - 54.98 |
| 成交量 | |
| 平均成交量 | 702,133 |
| 市值 | 3.714B |
| Beta 值 (5 年，每月) | 0.66 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -8.25 |
| 業績公佈日 | 2024年5月02日 - 2024年5月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 89.30 |
ZacksUltragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.
Insider Monkey10 NASDAQ Stocks with Biggest Upside
In this article, we discuss the 10 NASDAQ stocks with the biggest upside. To skip our detailed analysis, go directly to the 5 NASDAQ Stocks with Biggest Upside. The Nasdaq Composite was the worst performer among the major market indices in 2022 and made a stellar comeback in 2023. The index was down 33% at […]
Insider Monkey10 Biotech Stocks with Huge Potential
In this article, we will take a look at the 10 biotech stocks with huge potential. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Biotech Stocks with Huge Potential. Recent developments, technological as well as optimism related to interest rate reductions, have led to […]
